VSTM (VSTM) Stock Analysis
Verdict: HOLD
Verastem's $205M cash gives an 18-month trial runway, but $137.5M annual burn and zero insider buys preserve steep dilution risks.
Investment score: 46/100
The AI model rates VSTM as a HOLD. Although technical momentum (+55.0% over 90 days) and Wall Street price targets ($14.43 average) reflect excitement around VS-6766 clinical trials, heavy cash burn ($137.51M in 2025) and zero insider buying present substantial dilution risk before potential 2027 commercialization.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| PROK | -3.29 | -0.40 | 770.75 | -3.48 | — | -106.00 |
| TECX | -6.18 | 2.39 | 0.00 | -3.71 | — | 0.00 |
| PRME | -2.90 | 14.18 | 141.24 | -3.55 | — | -46.13 |
| RGNX | -2.21 | 6.16 | 2.48 | -3.34 | — | -1.13 |